Developing new antiviral agents for influenza treatment: What does the future hold?

Clinical Infectious Diseases

Volumn 48, Issue SUPPL. 1, 2009, Pages

  Hayden, Frederick ^a,b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ALPHA INTERFERON; AMANTADINE; ANTIVIRUS AGENT; CS 8958; DAS 181; FLUDASE; INTERFERON; OSELTAMIVIR; PERAMIVIR; R 118958; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; T 705; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL RESISTANCE; AVIAN INFLUENZA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; IC 50; IN VITRO STUDY; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H5N1; MORTALITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; CYCLOPENTANES; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE; PYRAZINES; RECOMBINANT FUSION PROTEINS; ZANAMIVIR;

EID: 57749187455     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/591851     Document Type: Review

References (77)

1. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A(H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:1175-81.
2. Deyde VM, Xu X, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249-57.
3. World Health Organization (WHO). Epidemic and pandemic alert and response (EPR): influenza A(H1N1) virus resistance to oseltamivir. Geneva: WHO, 6 March 2008. Available at: http://www.who.int/csr/disease/influenza/h1n1_table/ en/index.html. Accessed 7 March 2008.
4. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45:1568-75.
5. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12:501-8.
6. Lee N, Cockram C, Chan P, Hui D, Choi KW, Sung J. Antiviral treatment for patients hospitalized with severe influenza may affect clinical outcomes. Clin Infect Dis 2008; 46:1323-4.
7. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Update on avian influenza A(H5N1) virus infection in humans. N Engl J Med 2008; 358:261-73.
8. Roberts NA. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc Lond B Biol Sci 2001; 356:1895-7.
9. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35:1741-7.
10. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696-702.
11. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-33 (erratum: Pediatr Infect Dis J 2001; 20:421).
12. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987; 80:275-82.
13. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55(Suppl 1):i5-21.
14. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004; 364:759-65.
15. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003; 188:57-61.
16. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760-4.
17. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26:1418-24.
18. Smith NM, Bresee JS, Shay DK, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-10):1-42.
19. Cox NJ. FDA H5N1 update: classification of H5N1 viruses and development of vaccine reference strains. US Food and Drug Administration Vaccines and Related Biological Products Advisory Committee presentation (Gaithersburg, Maryland), 2007. Available at: http://www.fda.gov/ohrms/dockets/AC/07/ slides/2007-4282S2_9.ppt. Accessed 17 August 2007.
20. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A(H5N1) infection in humans. N Engl J Med 2005; 353:1374-85.
21. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis 2006; 194(Suppl 2):S133-8.
22. Neuraminidase Inhibitor Susceptibility Network. Use of influenza antivirals during 2003-2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec 2005; 80:156.
23. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly Epidemiol Rec 2007; 82:149-50.
24. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297:1435-42.
25. World Health Organization (WHO). Epidemic and pandemic alert and response (EPR): WHO/ECDC frequently asked questions for oseltamivir resistance. Geneva: WHO, 15 February 2008. Available at: http://www.who.int/csr/disease/ influenza/oseltamivir_faqs/en/index.html. Accessed 7 March 2008.
26. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A(H5N1) infection. N Engl J Med 2005; 353:2667-72.
27. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515-20.
28. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the Neuraminidase Inhibitor Susceptibility Network. J Clin Microbiol 2003; 41:742-50.
29. Chik KW, Li CK, Chan PK, et al. Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. Hong Kong Med J 2004; 10:103-6.
30. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis 2007; 45:187-93.
31. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006; 85:278-87.
32. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39:1300-6.
33. Machado CM, Boas LS, Mendes AV, et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 2004; 34:111-4.
34. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 2001; 45:3403-8.
35. Kawai N, Ikematsu H, Iwaki N, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005; 40:1309-16.
36. Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43:439-44.
37. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44:197-202.
38. Update: WHO-confirmed human cases of avian influenza A(H5N1) infection, 25 November 2003-24 November 2006. Wkly Epidemiol Rec 2007; 82:41-7.
39. Schünemann HJ, Hill SR, Kakad M, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A(H5N1) virus. Lancet Infect Dis 2007; 7:21-31.
40. World Health Organization (WHO). Epidemic and pandemic alert and response (EPR): clinical management of human infection with avian influenza A(H5N1) virus; updated advice. Geneva: WHO, 15 August 2007. Available at: http://www.who.int/csr/disease/avian_influenza/guidelines/clinicalmanage07/en/ index.html. Accessed 5 September 2007.
41. World Health Organization (WHO). Epidemic and pandemic alert and response (EPR): the second WHO consultation on clinical aspects of human infection with avian influenza A(H5N1) virus (Antalya, Turkey). Geneva: WHO, 2007. Available at: http://www.who.int/csr/disease/influenza/meeting2007_03_19/en/ index.html. Accessed 4 January 2008.
42. De Clercq E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 2006; 5:1015-25.
43. Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des 2007; 13:3531-42.
44. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antivir Res 2008; 78:91-102.
45. Medeiros R, Rameix-Welti MA, Lorin V, et al. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A(H1N1) virus. Antivir Ther 2007; 12:571-6.
46. Taylor WR, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS ONE 2008; 3:e3410.
47. Cass LM, Efthymiopoulous C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36(Suppl 1):1-11.
48. Calfee DP, Peng AW, Cass LM, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Agents Chemother 1999; 43:1616-20.
49. Stittelaar KJ, Tisdale M, van Amerongen G, et al. Evaluation of intravenous zanamivir against experimental influenza A(H5N1) virus infection in the cynomolgus macaques. Antivir Res 2008; 80:225-8.
50. Higgs ES, Hayden FG, Chotpitayasunondh T, Whitworth J, Farrar J. The Southeast Asia Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor. Antivir Res 2008; 78:64-8.
51. Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with highly virulent influenza virus A/Vietnam/1203/04(H5N1). Virology 2008; 374:198-209.
52. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006; 69:39-45.
53. Kilpatrick JM, Harman LA, Collis PJ, Aitee G, Mead E, Alexander WJ. Pharmacokinetics and safety of peramivir by intramuscular administration [abstract P916]. In: Program and abstracts of the Options for the Control of Influenza VI Conference (Toronto). London: International Society for Influenza and Other Respiratory Virus Diseases, 2007.
54. Kohno S, Kida H, Mizuguchi M, Shimada J. A double-blind, placebo-controlled study of intravenous peramivir in acute influenza patients [abstract 302(V)]. Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting (Washington, DC). Washington, DC: American Society for Microbiology, 2008:328.
55. Macdonald SJF, Watson KG, Cameron R, et al. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at once-weekly dosing regimen. Antimicrob Agents Chemother 2004; 48:4542-9.
56. Rennecke J, Hirota T, Puchler K. R-118958, a unique anti-influenza agent: safety, tolerability and pharmacokinetics (PK) in healthy male volunteers [abstract F-1834]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003. Available at: http://gateway.nlm.nih.gov/ MeetingAbstracts/102266075.html. Accessed August 2007.
57. 105. Biota Holdings. LANI phase II completed - phase III scheduled [press release]. Melbourne: Biota Holdings, 31 July 2008.
58. Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46:977-81.
59. Furuta Y, Takahashi K, Kuno-Maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49:981-6.
60. Sidwell RW, Barnard DL, Day CW, et al. Efficacy of orally administered T-705 on lethal avian influenza A(H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51:845-51.
61. Malakhov MP, Aschenbrenner LM, Smee DF, et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006; 50:1470-9.
62. Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196:1493-9.
63. Ison MG, Gnann JW Jr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. NIAID Collaborative Antiviral Study Group. Antivir Ther 2003; 8:183-90.
64. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 2007; 12:363-70.
65. Lavrov SV, Eremkina EI, Orlova TG, Galegov GA, Soloviev VD, Zhdanov VM. Combined inhibition of influenza virus reproduction in cell culture using interferon and amantadine. Nature 1968; 217:856-7.
66. D'Agostini C, Palamara AT, Favalli C, et al. Efficacy of combination therapy with amantadine, thymosin alpha 1 and alpha/beta interferon in mice infected with influenza A virus. Int J Immunopharmacol 1996; 18:95-102.
67. Sidwell RW, Bailey KW, Wong MH, Huffman JH. In vitro and in vivo sensitivity of a non-mouse-adapted influenza A (Beijing) virus infection to amantadine and ribavirin. Chemotherapy 1995; 41:455-61.
68. Galabov AS, Simeonova L, Gegova G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A(H3N2) influenza virus in mice. Antivir Chem Chemother 2006; 17:251-8.
69. Ilyushina NA, Hay A, Yilmaz N, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 2008; 52:3889-97.
70. Hayden FG, Schlepushkin AN, Pushkarskaya NL. Combined interferon-alpha 2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother 1984; 25:53-7.
71. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A(H5N1) infection. N Engl J Med 2007; 357:1450-1.
72. Ong AK, Hayden FG. John F. Enders Lecture 2006: antivirals for influenza. J Infect Dis 2007; 196:181-90.
73. Hayden FG. Antivirals for influenza: historical perspectives and lessons learned. Antivir Res 2006; 71:372-8.
74. Stein DS, Creticos CM, Jackson GG, et al. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother 1987; 31:1285-7.
75. Hayden FG, Sable CA, Connor JD, Lane J. Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection. Antivir Ther 1996; 1:51-6.
76. Simmons CP, Bernasconi NL, Suguitan AL, et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007; 4:e178.
77. Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 2006; 12:489.